Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Dec 4:11:1495346.
doi: 10.3389/fnut.2024.1495346. eCollection 2024.

Study on the mechanism of lactic acid bacteria and their fermentation broth in alleviating hyperuricemia based on metabolomics and gut microbiota

Affiliations

Study on the mechanism of lactic acid bacteria and their fermentation broth in alleviating hyperuricemia based on metabolomics and gut microbiota

Lijuan Rao et al. Front Nutr. .

Abstract

Introduction: Hyperuricemia (HUA) is a metabolic disease caused by purine metabolism disorders in the body. Lactic acid bacteria (LAB) and their fermentation broth have the potential to alleviate hyperuricemia, but the potential mechanism of action is still unclear.

Methods: The LAB with high inhibitory activity against xanthine oxidase (XOD) were screened out. Then the fermentation broth, fermentation supernatant and fermentation bacteria after fermentation of these LAB were administered into HUA mice, respectively.

Results: Lactobacillus reuteri NCUF203.1 and Lactobacillus brevis NCUF207.7, of which fermentation supernatant had high inhibitory activity against XOD, were screened out and administered into HUA mice. Among them, L. reuteri strain, L. reuteri fermentation broth, L. brevis fermentation broth and L. brevis fermentation supernatant could significantly reduce serum uric acid levels and inhibited the liver XOD activity in HUA mice. The GC-MS metabolomics analysis of colon contents showed that supplementation of these four substances could partially reverse the down-regulation of energy metabolism pathways such as ketone body metabolism, pyruvate metabolism and citric acid cycle in HUA mice. It could also regulate amino acid metabolism pathways such as alanine metabolism, arginine and proline metabolism, glycine and serine metabolism, and repair the disorders of amino acid metabolism caused by HUA. In addition, the intervention of L. brevis fermentation broth and L. brevis fermentation supernatant may also accelerate the catabolism of uric acid in the intestine by up-regulating the urea cycle pathway. Fecal 16S rRNA sequencing analysis showed that their intervention increased the diversity of gut microbiota in HUA mice and alleviated the gut microbiota dysregulation caused by HUA.

Discussion: These results indicated that the LAB and their fermentation broth may play a role in alleviating HUA by regulating intestinal metabolism and gut microbiota.

Keywords: Lactobacillus brevis; Lactobacillus reuteri; gut microbiota; hyperuricemia; metabolomics.

PubMed Disclaimer

Conflict of interest statement

GF was employed by International Institute of Food Innovation Co., Ltd. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

Figure 1
Figure 1
Experimental chart of lactic acid bacteria and their fermentation broth in treatment of HUA mice.
Figure 2
Figure 2
Inhibition rate of xanthine oxidase (XOD) by fermentation supernatant of lactic acid bacteria. Different letters indicate significant differences between groups (p < 0.05).
Figure 3
Figure 3
Changes of serum uric acid (A), serum creatinine (B), serum urea nitrogen (C) and hepatic xanthine oxidase activity (D) of mice. Different letters indicate significant differences between groups (p < 0.05).
Figure 4
Figure 4
Obtaining differential metabolites based on multivariate data analysis (A,C,E,G,I,K,M,O were OPLS-DA score chart; B,D,F,H,J,L,N,P were volcanic maps).
Figure 5
Figure 5
Column diagram of metabolite enrichment analysis. Panel (A) was the metabolic pathways changed in HUA group compared with CON group; Panels (B–H) were the metabolic pathways changed in ALP group, LB group, LBC group, LBS group, LR group, LRC group and LRS group compared with HUA group, respectively.
Figure 6
Figure 6
Effects of lactic acid bacteria and their fermentation broth on the gut microbiota of hyperuricemic mice. (A) Species annotation by phylum level. (B) Species annotation by genus level. (C) The relative abundance of Firmicutes. (D) The relative abundance of Verrucomicrobia. (E) The relative abundance of Akkermansia. (F) The relative abundance of Lactobacillus. (G) The relative abundance of Lachnospiraceae_FCS020_group. (H) α diversity indicated by Shannon index. (I) β diversity based on PCoA analysis. (#p < 0.05, ##p < 0.01, compare with CON group, *p < 0.05, **p < 0.01, compare with HUA group).
Figure 7
Figure 7
Difference analysis of KEGG metabolic pathway in gut microbiota of mice. Panel (A) was the metabolic pathways changed in HUA group compared with CON group; Panels (B–H) were the metabolic pathways changed in ALP group, LB group, LBC group, LBS group, LR group, LRC group and LRS group compared with HUA group, respectively (*p < 0.05, **p < 0.01).

Similar articles

Cited by

References

    1. Okamoto K, Eger BT, Nishino T, Kondo S, Pai EF, Nishino T. An extremely potent inhibitor of xanthine oxidoreductase. Crystal structure of the enzyme-inhibitor complex and mechanism of inhibition. J Biol Chem. (2003) 278:1848–55. doi: 10.1074/jbc.M208307200, PMID: - DOI - PubMed
    1. Grassi D, Ferri L, Desideri G, Giosia PD, Cheli P, Pinto RD, et al. . Chronic hyperuricemia, uric acid deposit and cardiovascular risk. Curr Pharm Des. (2013) 19:2432–8. doi: 10.2174/1381612811319130011, PMID: - DOI - PMC - PubMed
    1. Storhaug HM, Norvik JV, Toft I, Eriksen BO, Løchen ML, Zykova S, et al. . Uric acid is a risk factor for ischemic stroke and all-cause mortality in the general population: a gender specific analysis from the Tromsø study. BMC Cardiovasc Disord. (2013) 13:115. doi: 10.1186/1471-2261-13-115, PMID: - DOI - PMC - PubMed
    1. Zalawadiya SK, Veeranna V, Mallikethi-Reddy S, Bavishi C, Lunagaria A, Kottam A, et al. . Uric acid and cardiovascular disease risk reclassification: findings from NHANES III. Eur J Prev Cardiol. (2015) 22:513–8. doi: 10.1177/2047487313519346, PMID: - DOI - PubMed
    1. Shia MH, Lazo M, Liub SH, Bonekamp S, Hernaez R, Clark JM. Association between serum uric acid and non-alcoholic fatty liver disease in the US population. J Formos Med Assoc. (2015) 114:314–20. doi: 10.1016/j.jfma.2012.11.014, PMID: - DOI - PMC - PubMed

LinkOut - more resources